Overall, by boosting AMPK, these drugs counter metabolic reprogramming: they inhibit mTORC1 and even the CFTR channel responsible for fluid secretion, yielding a dual effect on cyst growth and fluid accumulation. The gene discussed is CFTR; the disease is cyst.